American International Group, Inc. C4 Therapeutics, Inc. Transaction History

American International Group, Inc.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	BUY	$3.1 - $9.02 $1,255 - $3,653	405 Added 2.04%	20,302 $63,000
Q4 2022 Feb 10, 2023	SELL	$5.42 - $10.24 $395 - $747	-73 Reduced 0.37%	19,897 $117,000
Q3 2022 Nov 14, 2022	BUY	$8.03 - $12.77 $2,264 - $3,601	282 Added 1.43%	19,970 $175,000
Q2 2022 Aug 12, 2022	BUY	$5.06 - $26.46 $2,565 - $13,415	507 Added 2.64%	19,688 $148,000
Q1 2022 May 13, 2022	SELL	$19.99 - $33.23 $27,006 - $44,893	-1,351 Reduced 6.58%	19,181 $465,000
Q4 2021 Feb 11, 2022	SELL	$29.39 - $46.86 $18,045 - $28,772	-614 Reduced 2.9%	20,532 $661,000
Q3 2021 Nov 12, 2021	BUY	$35.91 - $50.5 $66,397 - $93,374	1,849 Added 9.58%	21,146 $945,000
Q2 2021 Aug 13, 2021	BUY	$30.39 - $42.18 $397,410 - $551,587	13,077 Added 210.24%	19,297 $730,000
Q1 2021 May 07, 2021	BUY	$31.96 - $46.5 $511 - $744	16 Added 0.26%	6,220 $230,000
Q4 2020 Feb 12, 2021	BUY	$22.8 - $37.05 $141,451 - $229,858	6,204 New	6,204 $206,000

130

63.5M

670K

54.8K

Ticker CCCC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,913,800
Market Cap $208M
Description
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting ...

Get notified when there are updates to the investment portfolio of American International Group, Inc., based on Form 13F filings with the SEC.

Stay updated on American International Group, Inc. with notifications on news.